Navigation Links
Arthrosurface Hits a $100 Million Milestone
Date:4/23/2012

FRANKLIN, Mass., April 23, 2012 /PRNewswire/ -- Arthrosurface, Inc. (www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, announced that, in March, it surpassed $100 Million in cumulative net revenue. While this milestone is a significant financial achievement for the Company, its management believes that this milestone evidences the ever growing population of patients seeking alternatives to total joint replacement procedures. "Joint preservation, getting patients back to an active lifestyle and delaying conventional joint replacements has been our goal from the beginning," said Steve Ek, COO.

Arthrosurface contends it is the first and only company to develop a line of anatomic inlay implants for early joint disease and remains the leader in patient-matching metallic resurfacing. With more than 160 different implant sizes and shapes, the Arthrosurface joint platform could be considered the best first implant for early joint arthritis. Its resurfacing implants are thin, contoured, sized according to the defect and shaped to the patient's native joint surface. It is believed that there is no other orthopaedics company in the world with products that allow surgeons to intraoperatively and directly assess the joint status and choose a matching implant that, during the surgical procedure, serves the specific clinical need of the patient. With Arthrosurface's HemiCAP® resurfacing, the implant is matched to the patient. This implant-fitting concept is contrary to standard joint replacement where the patient is "fitted" to an implant through a series of large bone and soft tissue cuts.

Arthrosurface's President, Steve Tallarida, said, "We knew the idea of intervening sooner rather than later, when joint damage is limited, went against the conventional wisdom of traditional orthopaedics. In the world of total joints, treatment is typically delayed until significant joint destruction has occurred. We decided to take our cue from other disciplines, such as cardiology and dentistry, where stents and fillings are the first line choices for early intervention. Patients should have the option of considering an interim treatment in order to resume a normal lifestyle while hopefully delaying joint disease progression." 


'/>"/>
SOURCE Arthrosurface, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arthrosurface Crosses the 30,000 Patient and 100 Publication Milestones
2. Arthrosurface Launches Worlds First Talus Resurfacing Implant for the Ankle
3. Arthrosurface Continues to Expand into Fast Growing Shoulder Market
4. Arthrosurface® Hits the 20,000 Implant Milestone
5. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
6. Delcath Systems, Inc. Secures $20 Million Credit Facility
7. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
8. One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource
9. Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering
10. Comprehensive Care Corporation Doubles Its 2011 Revenues to Over $71 Million
11. Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology:
(Date:5/27/2016)... SC (PRWEB) , ... May 27, 2016 , ... ... a line of classic American timber frame barn kits, which can be found on ... are inspired by historic American barn plans, and they highlight the craftsmanship of timber ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... An ... bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It ... leading advocates, associations and industry leaders such as Bioness. , As patients ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... installment is bolstered by inspiring human interest stories, courtesy of leaders in the ... and tech within the industry, from leading advocates and associations—namely Jones & Bartlett ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center ... proof of successfully certified products, services and staff. , Validation Center is ISO17025 ...
Breaking Medicine News(10 mins):